| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $634,145 ) |
| | 2025 | 2025 | ORPHAGEN PHARMACEUTICALS, INC. | 2727 MORAVA PL | SAN DIEGO | CA | 92110-2360 | SAN DIEGO | USA | R44DK136458 | A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells | 001 | 2 | NIH | 7/16/2025 | $634,145 |
| | 2025 | 2024 | ORPHAGEN PHARMACEUTICALS, INC. | 2727 MORAVA PL | SAN DIEGO | CA | 92110-2360 | SAN DIEGO | USA | R44DK136458 | A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells | 000 | 1 | NIH | 7/14/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,077,526 ) |
| | 2024 | 2024 | ORPHAGEN PHARMACEUTICALS, INC. | 11558 SORRENTO VALLEY RD | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R44DK136458 | A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells | 001 | 1 | NIH | 9/6/2024 | -$1,078,081 |
| | 2024 | 2024 | ORPHAGEN PHARMACEUTICALS, INC. | 11558 SORRENTO VALLEY RD | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R44DK136458 | A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells | 001 | 1 | NIH | 9/6/2024 | $1,078,081 |
| | 2024 | 2024 | ORPHAGEN PHARMACEUTICALS, INC. | 11558 SORRENTO VALLEY RD | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R44DK136458 | A novel, pleiotropic oral drug class that inhibits gut migration of activated T cells | 000 | 1 | NIH | 9/5/2024 | $1,078,081 |
| | 2024 | 2022 | ORPHAGEN PHARMACEUTICALS, INC. | 11558 SORRENTO VALLEY RD | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R44CA265639 | Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer | 000 | 2 | NIH | 11/20/2023 | -$555 |
|
| Issue Date FY: 2023 ( Subtotal = $0 ) |
| | 2023 | 2022 | ORPHAGEN PHARMACEUTICALS, INC. | 11558 SORRENTO VALLEY RD | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R44CA265639 | Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer | 000 | 2 | NIH | 5/1/2023 | $0 |
| | 2023 | 2020 | ORPHAGEN PHARMACEUTICALS, INC. | 11558 SORRENTO VALLEY RD | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R44HD100256 | Translational feasibility of an oral, non-hormonal, male contraceptive pill | 000 | 2 | NIH | 8/7/2023 | $0 |
|
| Issue Date FY: 2022 ( Subtotal = $693,171 ) |
| | 2022 | 2022 | ORPHAGEN PHARMACEUTICALS, INC. | 11558 SORRENTO VALLEY RD STE 4 | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R44CA265639 | Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer | 000 | 2 | NIH | 6/30/2022 | $693,171 |
|
| Issue Date FY: 2021 ( Subtotal = $1,306,362 ) |
| | 2021 | 2021 | ORPHAGEN PHARMACEUTICALS, INC. | 11558 SORRENTO VALLEY RD STE 4 | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R44CA265639 | Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer | 000 | 1 | NIH | 7/5/2021 | $1,306,362 |
|
| Issue Date FY: 2020 ( Subtotal = $719,059 ) |
| | 2020 | 2020 | ORPHAGEN PHARMACEUTICALS, INC. | 11558 SORRENTO VALLEY RD STE 4 | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R44HD100256 | Translational feasibility of an oral, non-hormonal, male contraceptive pill | 001 | 2 | NIH | 7/24/2020 | $719,059 |
| | 2020 | 2019 | ORPHAGEN PHARMACEUTICALS, INC. | 11558 SORRENTO VALLEY RD STE 4 | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R44HD100256 | Translational feasibility of an oral, non-hormonal, male contraceptive pill | 000 | 1 | NIH | 7/23/2020 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $1,093,784 ) |
| | 2019 | 2019 | ORPHAGEN PHARMACEUTICALS | 11558 SORRENTO VALLEY RD STE 4 | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R44HD100256 | Translational feasibility of an oral, non-hormonal, male contraceptive pill | 000 | 1 | NIH | 8/12/2019 | $1,093,784 |
|
| Issue Date FY: 2018 ( Subtotal = $0 ) |
| | 2018 | 2016 | ORPHAGEN PHARMACEUTICALS | 11558 SORRENTO VALLEY RD STE 4 | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R43HL124897 | HLS-Small Molecule Discovery at Novel Target for Fetal Hemoglobin Induction | 000 | 2 | NIH | 12/21/2017 | $0 |
| | 2018 | 2015 | ORPHAGEN PHARMACEUTICALS | 11558 SORRENTO VALLEY RD STE 4 | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R43CA200076 | Orphan Nuclear Receptor as Novel Drug Discovery Target for Cancer Immunotherapy | 000 | 1 | NIH | 11/20/2017 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $1,000 ) |
| | 2017 | 2014 | ORPHAGEN PHARMACEUTICALS | 11558 SORRENTO VALLEY RD STE 4 | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R43TR000976 | Pharmacological Suppression of Rod Opsin as Therapy for Retinitis Pigmentosa | 000 | 2 | NIH | 6/15/2017 | $1,000 |
| | 2017 | 2014 | ORPHAGEN PHARMACEUTICALS | 11558 SORRENTO VALLEY RD STE 4 | SAN DIEGO | CA | 92121-1312 | SAN DIEGO | USA | R43DK102221 | Small Molecule Target for Inhibition of Cortisol in Cushing's Syndrome | 000 | 1 | NIH | 2/6/2017 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $160,677 ) |
| | 2016 | 2016 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121-2804 | SAN DIEGO | USA | R43HL124897 | HLS-Small Molecule Discovery at Novel Target for Fetal Hemoglobin Induction | 000 | 2 | NIH | 7/25/2016 | $160,677 |
|
| Issue Date FY: 2015 ( Subtotal = $389,328 ) |
| | 2015 | 2015 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121-2804 | SAN DIEGO | USA | R43CA200076 | Orphan Nuclear Receptor as Novel Drug Discovery Target for Cancer Immunotherapy | 000 | 1 | NIH | 7/1/2015 | $224,954 |
| | 2015 | 2015 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121-2804 | SAN DIEGO | USA | R43HL124897 | HLS-Small Molecule Discovery at Novel Target for Fetal Hemoglobin Induction | 000 | 1 | NIH | 8/18/2015 | $164,374 |
|
| Issue Date FY: 2014 ( Subtotal = $445,390 ) |
| | 2014 | 2014 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121-2804 | SAN DIEGO | USA | R43DK102221 | Small Molecule Target for Inhibition of Cortisol in Cushing's Syndrome | 000 | 1 | NIH | 9/18/2014 | $223,229 |
| | 2014 | 2014 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121-2804 | SAN DIEGO | USA | R43TR000976 | Pharmacological Suppression of Rod Opsin as Therapy for Retinitis Pigmentosa | 000 | 2 | NIH | 6/6/2014 | $222,161 |
|
| Issue Date FY: 2013 ( Subtotal = $224,474 ) |
| | 2013 | 2013 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121-2804 | SAN DIEGO | USA | R43TR000976 | Pharmacological Suppression of Rod Opsin as Therapy for Retinitis Pigmentosa | 000 | 1 | NIH | 5/28/2013 | $224,474 |
|
| Issue Date FY: 2012 ( Subtotal = $250,507 ) |
| | 2012 | 2012 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121-2804 | SAN DIEGO | USA | R43CA163009 | NEURAL STEM CELL-SELECTIVE DRUG TARGET FOR SMALL MOLECULE THERAPY OF BRAIN TUMORS | 000 | 1 | NIH | 7/16/2012 | $250,507 |
| | 2012 | 2010 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R44MH075461 | NOVEL CNS TARGET FOR SLEEP-WAKE AND PSYCHIATRIC DISORDERS | 000 | 4 | NIH | 7/12/2012 | $0 |
|
| Issue Date FY: 2011 ( Subtotal = $341,170 ) |
| | 2011 | 2011 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121-2804 | SAN DIEGO | USA | R43HD068078 | A NOVEL TARGET FOR THE TREATMENT OF ENDOMETRIOSIS | 000 | 1 | NIH | 9/17/2011 | $220,839 |
| | 2011 | 2011 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121-2804 | SAN DIEGO | USA | R43CA150540 | INHIBITOR OF ADRENAL STEROID SYNTHESIS FOR CANCER TREATMENT | 000 | 2 | NIH | 6/3/2011 | $120,331 |
|
| Issue Date FY: 2010 ( Subtotal = $1,085,607 ) |
| | 2010 | 2010 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121-2804 | SAN DIEGO | USA | R43CA150540 | INHIBITOR OF ADRENAL STEROID SYNTHESIS FOR CANCER TREATMENT | 000 | 1 | NIH | 5/26/2010 | $400,027 |
| | 2010 | 2010 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121-2804 | SAN DIEGO | USA | R44MH075461 | NOVEL CNS TARGET FOR SLEEP-WAKE AND PSYCHIATRIC DISORDERS | 000 | 3 | NIH | 11/23/2009 | $204,192 |
| | 2010 | 2010 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121 | SAN DIEGO | USA | R44MH075461 | NOVEL CNS TARGET FOR SLEEP-WAKE AND PSYCHIATRIC DISORDERS | 002 | 3 | NIH | 6/20/2010 | $0 |
| | 2010 | 2010 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121-2804 | SAN DIEGO | USA | R44MH075461 | NOVEL CNS TARGET FOR SLEEP-WAKE AND PSYCHIATRIC DISORDERS | 003 | 4 | NIH | 8/6/2010 | $481,388 |
| | 2010 | 2009 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121-2804 | SAN DIEGO | USA | R44MH075461 | NOVEL CNS TARGET FOR SLEEP-WAKE AND PSYCHIATRIC DISORDERS | 001 | 3 | NIH | 2/20/2010 | $0 |
|
| Issue Date FY: 2009 ( Subtotal = $479,791 ) (Continued on the next page) |
| | 2009 | 2009 | ORPHAGEN PHARMACEUTICALS | 5310 EASTGATE MALL | SAN DIEGO | CA | 92121-2804 | SAN DIEGO | USA | R44MH075461 | NOVEL CNS TARGET FOR SLEEP-WAKE AND PSYCHIATRIC DISORDERS | 000 | 3 | NIH | 9/29/2009 | $479,791 |
|
